{
  "success": true,
  "pagesUsed": [
    8,
    9,
    10
  ],
  "modelUsed": "gemini-3-pro-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%",
        "level": {
          "code": "Primary",
          "codeSystem": "USDM",
          "decode": "Primary"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Safety and Tolerability Objective",
        "text": "To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "PK Profile Objective",
        "text": "To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "PD Profile Objective",
        "text": "To characterize the PD profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "The proportion of patients achieving treatment success defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir within 30 minutes after administration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration.",
        "level": {
          "code": "Primary",
          "codeSystem": "USDM",
          "decode": "Primary"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Safety Parameters",
        "text": "SAE, TEAEs (including gastrointestinal, nasal, and non-nasal AEs), vital signs",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "PK Parameters",
        "text": "PK parameters include AUC, Cmax, Tmax",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_4",
        "name": "PD Parameters",
        "text": "PD parameters include BGmax and Tmax",
        "level": {
          "code": "Secondary",
          "codeSystem": "USDM",
          "decode": "Secondary"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 3,
      "exploratoryObjectives": 0,
      "totalEndpoints": 4,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Safety and Tolerability Objective",
        "text": "To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "PK Profile Objective",
        "text": "To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "PD Profile Objective",
        "text": "To characterize the PD profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "The proportion of patients achieving treatment success defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir within 30 minutes after administration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration.",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Safety Parameters",
        "text": "SAE, TEAEs (including gastrointestinal, nasal, and non-nasal AEs), vital signs",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "name": "PK Parameters",
        "text": "PK parameters include AUC, Cmax, Tmax",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "name": "PD Parameters",
        "text": "PD parameters include BGmax and Tmax",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacodynamic",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": []
  }
}